Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Doxorubicin 40Radiotherapy 30Ifosfamide 28Vincristine 27Cyclophosphamide 24Imatinib Mesylate 20Etoposide 20Dactinomycin 14Radiation 13Filgrastim 11Temozolomide 9Sunitinib 9Trabectedin 8Methotrexate 8Specimen Handling 7Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Chemotherapy, Adjuvant 6pazopanib 5nilotinib 5Zoledronic Acid 5Neoadjuvant Therapy 5Irinotecan 5Cisplatin 5Carboplatin 5X-Rays 4Vinorelbine 4Topotecan 4Surgical Procedures, Operative 4Procarbazine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × IDRX-42 × Sarcoma × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡